Literature DB >> 6344988

Production of growth-inhibitory activity in serum-free medium by human monocytic leukemia cells.

E V Gaffney, S C Tsai, M L Dell'Aquila, S E Lingenfelter.   

Abstract

Serum-free medium conditioned by activated cells of the acute monocytic leukemia line, THP-1, was examined for growth-inhibitory activity with several established human cell lines. Free-floating clusters of THP-1 cells were activated into adherent nonproliferating cells by a 24-hr exposure to 10(-7) M mezerein in Roswell Park Memorial Institute 1640 medium containing 1% fetal bovine serum. Adherent cells were incubated for an additional 24 hr in serum-free medium containing insulin (5 micrograms/ml). Dose-response studies revealed that a cervical carcinoma (HeLa), a melanoma (A375Ag5), and several mammary carcinoma cell lines (MCF-7, BT474, MDA-MB415, and T47D) were growth inhibited by this conditioned medium. We concluded, from the results of thymidine release assays and from experiments on reversibility, that inhibition was a cytostatic and not a cytolytic response. In contrast, THP-1 conditioned medium stimulated the growth of two mammary lines (ZR75-1 and HBL-100), a lung type II carcinoma (549), and a colon adenocarcinoma (SW48). Preliminary characterization showed that the inhibitory activity was stable to acid and urea treatment but was destroyed by trypsin and sodium dodecyl sulfate. Molecular sieve chromatography of acetic acid-extracted material separated the inhibitory and stimulatory components.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344988

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  2 in total

1.  Identification and characterization of a tumor-derived immunosuppressive glycoprotein from murine melanoma K-1735.

Authors:  J B Putnam; J A Roth
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

2.  Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment.

Authors:  Zhenghang Wang; Xiaochen Zhao; Chan Gao; Jifang Gong; Xicheng Wang; Jing Gao; Zhongwu Li; Jie Wang; Bo Yang; Lei Wang; Bei Zhang; Yifan Zhou; Dalei Wang; Xiaofang Li; Yuezong Bai; Jian Li; Lin Shen
Journal:  J Immunother Cancer       Date:  2020-11       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.